López-Carrasquillo Jonathan, Ramos-Plaza Vivianka Y, Cruz Myrella L, Rodriguez-Morales Bryan M, Sánchez Raphael, López Pablo, Chompré Gladys, Appleyard Caroline B
Department of Basic Sciences, Ponce Research Institute, Ponce Health Sciences University, Ponce, PR 00716, USA.
Biology and Biotechnology Department, Pontifical Catholic University of Puerto Rico, Ponce, PR 00716, USA.
Nutrients. 2025 Aug 22;17(17):2719. doi: 10.3390/nu17172719.
BACKGROUND/OBJECTIVE: Probiotic and vitamin D supplements are widely studied in clinical and animal studies as potential treatments for inflammatory bowel disease. However, their potential synergistic or additive effect in ameliorating colitis development is still poorly understood. The aim of this study was to investigate the potential beneficial enhancement of combining a mixed-strain probiotic with vitamin D supplementation in a colitis animal model.
After 5 days of acclimation, C57BL/6 mice received Vivomixx probiotic (at least 1 × 10 Colony-Forming Units) and/or vitamin D (5 IU/g) in drinking water and chow, respectively, for 7 days prior to intracolonic TNBS-induced colitis and until sacrifice. On day 10, animals were sacrificed, and colons were collected to assess colonic damage, cytokine and chemokine expression, total M1 macrophage phenotype, and neutrophil recruitment. Serum and fecal samples were collected to assess vitamin D levels and microbiome composition.
Administration of probiotic and vitamin D alone or combined decreased colonic damage and neutrophil recruitment and activity. This effect was associated with an increase in the active form of vitamin D in serum and mucosal barrier integrity. However, administration of probiotics and/or vitamin D did not modulate macrophage infiltration or the M1 pro-inflammatory phenotype.
These results suggest that combined probiotic and vitamin D supplementation attenuates TNBS-induced colitis by targeting neutrophil infiltration while enhancing the mucosal barrier. This alternative approach may offer protective potential for IBD management.
背景/目的:益生菌和维生素D补充剂作为炎症性肠病的潜在治疗方法,在临床和动物研究中得到了广泛研究。然而,它们在改善结肠炎发展方面的潜在协同或相加作用仍知之甚少。本研究的目的是在结肠炎动物模型中,研究混合菌株益生菌与维生素D补充剂联合使用的潜在有益增强作用。
适应5天后,C57BL/6小鼠在结肠内注射TNBS诱导结肠炎前7天,分别在饮用水和食物中接受维沃密克斯益生菌(至少1×10个菌落形成单位)和/或维生素D(5 IU/g),直至处死。在第10天,处死动物并收集结肠,以评估结肠损伤、细胞因子和趋化因子表达、总M1巨噬细胞表型和中性粒细胞募集。收集血清和粪便样本,以评估维生素D水平和微生物组组成。
单独或联合使用益生菌和维生素D可减少结肠损伤以及中性粒细胞募集和活性。这种作用与血清中维生素D活性形式的增加和黏膜屏障完整性有关。然而,益生菌和/或维生素D的使用并未调节巨噬细胞浸润或M1促炎表型。
这些结果表明,联合补充益生菌和维生素D可通过靶向中性粒细胞浸润同时增强黏膜屏障来减轻TNBS诱导的结肠炎。这种替代方法可能为炎症性肠病的管理提供保护潜力。